Press release content from Business Wire. The AP news staff was not involved in its creation.

Osmol Therapeutics Provides Corporate Update at BIOTECH SHOWCASE 2023

PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.
December 21, 2022 GMT

NEW HAVEN, Conn.--(BUSINESS WIRE)--Dec 21, 2022--

Osmol Therapeutics, today announced that it is presenting at BIOTECH SHOWCASE 2023, a leading investor conference focused on driving advances in therapeutic development taking place in San Francisco from January 9-11, 2023.

Presentation details:
Bob Linke, Chief Executive Officer, Osmol Therapeutics
January 9, 2023, at 9:00 a.m. PST
Hilton Union Square, 333 O’Farrell Street, Franciscan B (Ballroom Level), San Francisco CA

Registered attendees can view Osmol’s presentation live and access a recorded version beginning November 29th – six weeks prior to the actual event. With 24x7 on-demand access, attendees can view recorded presentations at their convenience when scheduling does not allow viewing during the main event week.

“There are currently no FDA-approved treatments for chemo-induced peripheral neuropathy (CIPN), a debilitating side effect most commonly associated with microtubule therapies such as taxanes,” said Bob Linke. “Based on the research of Dr. Barbara Ehrlich of Yale University, Osmol ’s lead drug candidate, OSM-0205, is designed to prevent the occurrence of CIPN. Our initial focus is on breast cancer where up to 80% of patients treated with taxanes develop CIPN. Half of these patients have their dose of chemotherapy reduced to address their CIPN since there are no disease modifying treatments available today, potentially negatively impacting patient outcomes. There is an urgent need for a therapy to prevent CIPN and we expect to begin a Phase 1 clinical trial of OSM-0205 in the first half of 2023.”

BIOTECH SHOWCASE, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry’s largest gatherings and busiest weeks.

“We are delighted that Osmol Therapeutics will be joining us in San Francisco and present at BIOTECH SHOWCASE this year,” said Sara Demy, CEO of Demy-Colton. “BIOTECH SHOWCASE is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”

About OSM-0205 and CIPN

Osmol’s lead drug, OSM-0205, is based on Dr. Barbara Ehrlich’s research in neuronal calcium sensor-1 (NCS1) at Yale University and is designed to prevent the off-target calcium surge caused by taxanes and potentially other chemotherapy treatments associated with peripheral nerve damage. Data from preclinical studies conducted by Osmol show that pre-treatment with OSM-0205 prevents the pathologic damage caused by these chemotherapy agents. Further, preliminary data in preclinical models suggests OSM-0205 may have utility in preventing chemotherapy induced cognitive impairment, an indication that will also be assessed by Osmol.

Osmol expects to initiate a Phase 1 bioavailability trial for the treatment of chemotherapy induced peripheral neuropathy in the first half of 2023.

About Osmol Therapeutics

Osmol Therapeutics is a privately held biopharma company focused on developing a treatment to prevent chemotherapy-induced peripheral neuropathy (CIPN) based on the ground-breaking work of Dr. Barbara Ehrlich. The company’s lead indication will be for the prevention of CIPN related to taxane treatment. As an example of the extent of this condition, up to 80% of taxane-treated patients with breast cancer have been reported to experience CIPN. For more information, please go to


BIOTECH SHOWCASE is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather at BIOTECH SHOWCASE during this bellwether week which sets the tone for the coming year. Now in its 15th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. BIOTECH SHOWCASE is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.

View source version on

CONTACT: Mariesa Kemble

Scient PR



SOURCE: Osmol Therapeutics

Copyright Business Wire 2022.

PUB: 12/21/2022 09:47 AM/DISC: 12/21/2022 09:47 AM